Several treatment modalities have become available for management of acute hereditary angioedema (HAE) attacks in the last 15 years. Preferred contemporary use of the treatments is “on demand,” because control remains with the patient and delays in treatment access avoided.
Four treatments are available:
— plasma-derived C1 inhibitor concentrate
- recombinant C1 inhibitor concentrate
- ecallantide
- icatibant
References:
Acute Management of Hereditary Angioedema Attacks http://buff.ly/2ryJDzV
Four treatments are available:
— plasma-derived C1 inhibitor concentrate
- recombinant C1 inhibitor concentrate
- ecallantide
- icatibant
References:
Acute Management of Hereditary Angioedema Attacks http://buff.ly/2ryJDzV